Tag: Eczema
FDA Expands Approval of Vtama to Include Atopic Dermatitis
The nonsteroidal topical treatment is approved for patients 2 years and older
FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
The monoclonal antibody treatment is for patients ages 12 years and older
Dupilumab Efficacious for Atopic Dermatitis in Young Children
Findings seen for children with and without comorbidities, such as asthma, allergic rhinitis, food allergies
Greater Fine Particulate Matter Linked to Increased Odds of Eczema
In multivariable analyses after adjustment for demographics and smoking status, odds ratio was 2.21 for eczema in areas with higher PM2.5
Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
Findings seen through 76 weeks of treatment for adolescents taking 15- or 30-mg doses for moderate-to-severe atopic dermatitis
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
Long-term efficacy seen for lebrikizumab every two weeks or every four weeks in moderate-to-severe atopic dermatitis
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
Approval is for new, first-line biologic treatment of eczema that is not well controlled with topicals in people 12 years and older
Link Between n-3 LCPUFA, Eczema Varies by Maternal COX1 Genotype
Risk for AD was lower in the n-3 LCPUFA versus placebo group among mothers with the TT genotype
Dietary Vitamin E May Be Protective Against Atopic Dermatitis
Vitamin C, retinol, and carotene are not causally tied to atopic dermatitis
Dupilumab Maintains Its Effectiveness Up to Five Years in Patients With Eczema
23.8 percent of patients discontinued dupilumab, with adverse events and ineffectiveness the most common reasons
